A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

Now Viewing

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment

Related Videos

Related Content

Advertisement

April 25th 2025

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

April 18th 2025

The Hidden Complexity of Reporting AEs

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

April 11th 2025

Subcutaneous Methotrexate Shows Promise Over Oral Route in Plaque Psoriasis Treatment

April 10th 2025

Icotrokinra Demonstrates Efficacy in Adolescents and Adults With Moderate to Severe Psoriasis in ICONIC-LEAD Phase 3 Study

Related Content

Advertisement

April 25th 2025

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

April 18th 2025

The Hidden Complexity of Reporting AEs

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

April 11th 2025

Subcutaneous Methotrexate Shows Promise Over Oral Route in Plaque Psoriasis Treatment

April 10th 2025

Icotrokinra Demonstrates Efficacy in Adolescents and Adults With Moderate to Severe Psoriasis in ICONIC-LEAD Phase 3 Study